Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cladribine: a multicenter, LOng-term efficacy and Biomarker Australian Study in patients with relapsing-remitting multiple sclerosis

Next Previous
Trial Profile

Cladribine: a multicenter, LOng-term efficacy and Biomarker Australian Study in patients with relapsing-remitting multiple sclerosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cladribine (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms CLOBAS

Most Recent Events

  • 13 Oct 2023 Results assessing changes in global DNA methylation in people with MS using blood DNA samples collected from a subset of prospectively followed cohort from this study presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
  • 13 Oct 2023 Results (from the first 30 months, n=156) assessing baseline parameters which predict the need for re-dosing first afterthe second year of cladribine use in pwMS presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
  • 01 May 2020 Results (n=18) of preliminary data of first course of dosing were presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top